Pharma-AI Collaborations Surge as Industry Nears a Period of Intensive Harvest

　　【Pharmaceutical Network Industry DynamicsIn recent years, AI technology has become an important core driving force in the pharmaceutical industry. Since 2025, many pharmaceutical companies in China and abroad have been utilizing AI technology to reduce costs and accelerate the R&D process.
 

Recently, Novartis announced a collaboration with UK-based Relation Therapeutics worth a total of $1.755 billion. This collaboration will combine Relation's AI-driven drug discovery platform and human data generation capabilities with Novartis' deep expertise in immunodermatology to jointly identify, validate, and advance "first-in-class" therapeutic targets for atopic diseases caused by immune dysregulation.
 

Relation is a platform-based biotechnology company dedicated to addressing significant unmet medical needs. Its core Lab-in-the-Loop™ closed-loop laboratory platform integrates human genetics, single-cell multi-omics data from patient tissues, functional experiments, and machine learning technologies, pioneering new paradigms in disease treatment.
 

Notably, Relation also reached a structurally similar agreement with GSK China in 2024. The collaboration, valued at over 500 million US dollars, will focus on identifying and validating new therapeutic targets for fibrotic diseases and osteoarthritis, aiming to advance the discovery and development of new drugs to address unmet medical needs of patients.
 

On December 9, Gan&Lee Pharmaceuticals announced that it had reached a metabolic disease AI peptide drug research and development collaboration and an AI technology platform usage authorization agreement with XtalPi. According to the agreement, Gan&Lee Pharmaceuticals will utilize XtalPi's proprietary AI peptide R&D platform, PepiX™, to focus on unmet core treatment needs in the field of metabolic diseases, accelerating the discovery and development process of novel peptide innovative drugs.
 

Gan&Lee Pharmaceuticals stated that it hopes to combine its deep understanding of diseases and drugs with XtalPi Holdings Limited's cutting-edge AI computing capabilities through this collaboration, exploring more efficient and intelligent new R&D pathways.
 

On November 10, Eli Lilly and Insilico Medicine reached a strategic cooperation in drug research and development. According to the official announcement, the cooperation amount exceeds 100 million US dollars. The two parties will combine the cutting-edge technical capabilities of Insilico Medicine's independently developed AI pharmaceutical platform Pharma.AI with Eli Lilly's profound accumulation in drug development and disease research to jointly accelerate the discovery and advancement of innovative therapies.
 

This collaboration marks Lilly's continued deepening layout in the artificial intelligence field, as the company has been increasing its investment in this area since 2025. On November 5, Ailux, a wholly-owned subsidiary of XtalPi, reached a multi-target strategic collaboration and platform licensing agreement with Lilly worth up to $345 million. The partnership will leverage Ailux’s proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, while also utilizing its AI antibody R&D platform to expedite internal pipeline research. In September 2025, Lilly announced the launch of its artificial intelligence and machine learning platform, Lilly TuneLab. According to Lilly’s estimates, the proprietary data contained within this platform is valued at over $1 billion.
 

In addition to the above pharmaceutical companies, there have been several collaborations in the AI field recently, such as Phare Bio partnering with Basilea to develop a new generation of broad-spectrum antibiotics, with Phare Bio designing molecules and Basilea handling subsequent development; AstraZeneca entering into a multi-year strategic partnership with Pangaea Data to scale the application of AI technology for more efficient patient identification and matching with clinical trials and treatment plans…
 

Overall, with the development of artificial intelligence technology, AI has become a key tool for pharmaceutical companies to break through the bottleneck of "low R&D efficiency and high costs." At present, pharmaceutical companies in China and abroad are increasingly focusing on collaborations with AI enterprises in areas such as drug development for specific diseases and optimization of clinical trials. The cooperation models are also showing a trend toward diversification. In the future, the AI-driven pharmaceutical industry will experience even more vigorous growth, with relevant commercial applications gradually being implemented, and the industry is expected to enter a period of substantial returns.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.